We are proud of this announcement from Prevail Therapeutics.
Prevail Therapeutics is pleased to announce a significant milestone in our Phase 1/2 PROPEL clinical trial for Parkinson’s disease with GBA1 mutations (PD-GBA): Cohort 1 is fully recruited, and we have now initiated enrollment of the 2nd cohort! This marks an exciting step in our journey to find effective treatments for PD-GBA. We extend our deepest gratitude to the dedicated clinical research teams, patient advocacy groups, and, most importantly, the patients and their families who entrust us with their care. As we continue on this journey, Prevail remains driven by our shared passion for improving health outcomes and enhancing quality of life for the rare diseases community. The PROPEL trial is a gene therapy study actively recruiting patients with PD-GBA, ages 35–80 years. To learn more about the PROPEL trial, please visit: https://bit.ly/45MwYud #ParkinsonsDisease #GeneTherapy #PDGBA #ClinicalTrials #ABCsOfPD #GoTeamFox #OutrunPD